IDH3A and central nervous system cancer: In their pilot study [23], Röhrich and colleagues characterized the uptake of FAP ligands in 18 glioma patients, 13 with isocitrate dehydrogenase (IDH)-wildtype glioblastoma WHO grade IV and 5 with IDH-mutant glioma.